ARTICLE | Clinical News
SGN-15: Development discontinued
July 11, 2005 7:00 AM UTC
In an open-label Phase II trial in NSCLC patients assessing the optimal dose schedule showed that administration of SGN-15, 3 days ahead of Taxotere, showed greater synergy and drug effect than when ...